Clinical Report: The Role of 2-Hydroxyglutarate in Cancer Pathways

Overview

This report discusses the significance of 2-hydroxyglutarate (2HG) in cancer biology, particularly its role as an oncometabolite that influences proto-oncogene activation and tumor progression. The review highlights the potential of 2HG as a biomarker and therapeutic target in cancer treatment.

Background

Cancer remains a leading cause of mortality globally, with metabolic alterations being a hallmark of its pathology. Understanding the role of metabolites like 2HG in cancer pathways is crucial for developing targeted therapies. The competitive inhibition of α-KG-dependent dioxygenases by 2HG can disrupt critical cellular processes, contributing to tumorigenesis and therapy resistance.

Data Highlights

No numerical data provided in the article.

Key Findings

• 2HG exists in two chiral forms, D-2HG and L-2HG, which mimic α-KG and inhibit α-KG-dependent dioxygenases.
• 2HG interferes with epigenetic regulation, redox balance, DNA repair, and cell signaling.
• The presence of 2HG is linked to tumor heterogeneity and therapy resistance.
• 2HG has potential as a biomarker for IDH mutations in various cancers.
• Targeting 2HG pathways may offer new therapeutic strategies to disrupt cancer signaling.

Clinical Implications

Clinicians should consider the role of 2HG in cancer metabolism when evaluating tumor biology and treatment options. The identification of IDH mutations and the presence of 2HG can guide therapeutic decisions and improve patient outcomes.

Conclusion

The review underscores the importance of 2HG in cancer pathways and its potential as a therapeutic target. Further research is needed to fully elucidate its role in cancer biology and treatment.

References

1. Gastric Cancer — Role of Metabolic Reprogramming in Gastric Cancer Associated with Helicobacter pylori Infection
2. Archives of Toxicology — The Role of Oxidative Stress and Antioxidant Defense in the Development and Progression of Cancer
3. the asco post — Can a Mitochondrial Antioxidant Drive Metastasis?
4. Journal of Gastroenterology — The Critical Function of SFRP2 in Enhancing Glycolysis and Disease Advancement in High-Risk Colorectal Cancer Patients Based on a Glycometabolism Prognostic Model
5. Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline Rapid Recommendation Update | Neuro-Oncology | Oxford Academic
6. Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma - PubMed
7. 2-Hydroxyglutarate magnetic resonance spectroscopy for preoperative IDH molecular profiling – A review of the literature and real-world clinical translation in a busy neurosurgical neuro-oncology unit
8. Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline Rapid Recommendation Update | Neuro-Oncology | Oxford Academic
9. Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma - PubMed
10. 2-Hydroxyglutarate magnetic resonance spectroscopy for preoperative IDH molecular profiling – A review of the literature and real-world clinical translation in a busy neurosurgical neuro-oncology unit - ScienceDirect